Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pre-expiry Januvia generics may test Merck’s resolve in India

This article was originally published in Scrip

Executive Summary

Mumbai-based Glenmark has introduced a cut-price version of Merck's diabetes therapies, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), on the Indian market ahead of the expected 2017 patent expiry date for the compounds. With Glenmark maintaining that its products are ‘non-infringing’, Merck – which has already made at least two separate attempts to adapt its commercial strategy to Indian conditions - will have to decide whether it wants to get involved in a David-versus-Goliath intellectual property rights battle.

You may also be interested in...



Januvia Generics Arrive In India

A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?

Januvia Generics Arrive: Can MSD Defend Its Turf In India?

A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the company respond with price cuts?

Big Pharma Restructures Commercial Teams In India

More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC020892

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel